Xiao Yao San, alone or combined with anxiolytics, assists in better improvement and safety in treating anxiety disorders compared to anxiolytics alone.
The methodology involved a systematic search on PubMed, Cochrane Library, EMBASE, Web of Science, and several Chinese databases for all randomized control trials (RCTs) that have evaluated the use of XYS for treating anxiety disorders until November 2021. The studies were independently screened, and data were extracted by two investigators who also assessed the risk of bias in the selected trials using RevMan5.3 software.
The meta-analysis result shows that the use of XYS, either on its own or together with anxiolytics, showed better improvements in anxiety-related symptoms and fewer adverse drug reactions compared to treatment with anxiolytics only. This suggests that XYS, whether used alone or in conjunction with anxiolytic agents, appears to offer a more effective and safer treatment option for anxiety disorders.
